Area II – Products and Structures
K1 Competence Center – Initiated by the Federal Ministry of Transport, Innovation &
Technology (MMVIT) and the Federal Ministry of Economics & Labour (BMWA).
Funded by FFG, Land Steiermark and Steirische Wirtschaftsförderung (SFG).
Area II – Products and Structures
Stefan Leitgeb
sleitgeb@tugraz.at 06.10.2010
Area 2 – Products and Structures
Area II nucleates research efforts focusing on experimental and computational studies to obtain
an understanding of product quality and behavior, as well as on structuring methods (e.g., nano-
particle formation, hierarchical particle technology, micro-particle formation, scalable production
processes, etc.). Area 2 can be divided in two divisions:
→ large molecule drugs
Goals:
→ small molecule drugs
Goals:
- Seite06.10.2010
RCPE - Area 2
2
→ Protein engineering and analysis for improved
formulation properties
→ Development of stable formulations
→ Investigation of inactivation pathways
→ Understanding aggregation propensities
→ Characterization of API – polymer interactions
→ Nano-particle formation processes
→ Development of stable formulations
→ Development of drug delivery systems
→ particle structuring methods
Production of pharmaceutical
proteins
Cloning into
expression
vectorTrans-
formation in
host cell
Fermen-
tation and
protein
expression
Storage
Main field of expertise:
pharmaceutical
development
- Seite06.10.2010 3
RCPE - Area 2
Identification
of target
protein
Isolation of
gene of
interest
Protein
purification
Packaging
Formulation
of protein
product
Manufacturing
Integrated quality by design approach:
Intelligent product design
Formulation of pharmaceutical
proteins
Process
engineering level
Stirring+
mixing
(Freeze)-
drying
Filtration Refolding
Freeze-
thaw
Crystal-
lisation
filling
storage transport
- Seite06.10.2010 4
RCPE - Area 2
API Formulation
Product at
customer
Molecular level
Shear
stress
Packaging
material
Surface
interactions
Hydration
effect
Phase
transition
Excipients
Formulation
conditions
Environ-
ment
One-stop shop
Pharmaceutical
proteins
- Seite06.10.2010
RCPE - Area 2
5
Formulation
Development
Influence of
process-relevant
parameters of
critical operations
on proteins
Modifications of
proteins for
improved
performance
Stability
investigation and
optimisation of
biopharma-
ceutical products
Fields of Expertise
Influence of critical process parameters (CPP)
on critical quality attributes (CQA)
Product optimisation
Computer simulations at various levels of theory
(QSAR, molecular dynamics, coarse grained, …)
Biophysical and biochemical characterisation of
- Seite
Biophysical and biochemical characterisation of
proteins
Stability and aggregation investigations
High-throughput formulation development and
optimisation
DoE
06.10.2010 6
RCPE - Area 2
Services
Experimental
High-throughput formulation
development of pharmaceutical proteins
and small molecules
Protein aggregate characterization
Stability testing of pharmaceutical
proteins under accelerated conditions
Computational - proteins
Rational protein design based on
molecular structure
Molecular dynamics simulations of
protein – small molecule interactions
- Seite
proteins under accelerated conditions
Biophysical and biochemical protein
characterization
06.10.2010
RCPE Präsentationstitel
7
Computational – small molecules
Virtual screening
In-silico lead optimisation
Solubility calculation of small molecules
Prediction of crystal structure /
polymorphs and morphologies / habits
Design and implementation of work flows
and data streams through scripting
General
Literature studies
Design and implementation of efficient
virtual work flows and data streams
through scripting (Knime, Phyton, Perl)

Rcpe Pharmaceutical Proteins

  • 1.
    Area II –Products and Structures K1 Competence Center – Initiated by the Federal Ministry of Transport, Innovation & Technology (MMVIT) and the Federal Ministry of Economics & Labour (BMWA). Funded by FFG, Land Steiermark and Steirische Wirtschaftsförderung (SFG). Area II – Products and Structures Stefan Leitgeb sleitgeb@tugraz.at 06.10.2010
  • 2.
    Area 2 –Products and Structures Area II nucleates research efforts focusing on experimental and computational studies to obtain an understanding of product quality and behavior, as well as on structuring methods (e.g., nano- particle formation, hierarchical particle technology, micro-particle formation, scalable production processes, etc.). Area 2 can be divided in two divisions: → large molecule drugs Goals: → small molecule drugs Goals: - Seite06.10.2010 RCPE - Area 2 2 → Protein engineering and analysis for improved formulation properties → Development of stable formulations → Investigation of inactivation pathways → Understanding aggregation propensities → Characterization of API – polymer interactions → Nano-particle formation processes → Development of stable formulations → Development of drug delivery systems → particle structuring methods
  • 3.
    Production of pharmaceutical proteins Cloninginto expression vectorTrans- formation in host cell Fermen- tation and protein expression Storage Main field of expertise: pharmaceutical development - Seite06.10.2010 3 RCPE - Area 2 Identification of target protein Isolation of gene of interest Protein purification Packaging Formulation of protein product Manufacturing Integrated quality by design approach: Intelligent product design
  • 4.
    Formulation of pharmaceutical proteins Process engineeringlevel Stirring+ mixing (Freeze)- drying Filtration Refolding Freeze- thaw Crystal- lisation filling storage transport - Seite06.10.2010 4 RCPE - Area 2 API Formulation Product at customer Molecular level Shear stress Packaging material Surface interactions Hydration effect Phase transition Excipients Formulation conditions Environ- ment
  • 5.
    One-stop shop Pharmaceutical proteins - Seite06.10.2010 RCPE- Area 2 5 Formulation Development Influence of process-relevant parameters of critical operations on proteins Modifications of proteins for improved performance Stability investigation and optimisation of biopharma- ceutical products
  • 6.
    Fields of Expertise Influenceof critical process parameters (CPP) on critical quality attributes (CQA) Product optimisation Computer simulations at various levels of theory (QSAR, molecular dynamics, coarse grained, …) Biophysical and biochemical characterisation of - Seite Biophysical and biochemical characterisation of proteins Stability and aggregation investigations High-throughput formulation development and optimisation DoE 06.10.2010 6 RCPE - Area 2
  • 7.
    Services Experimental High-throughput formulation development ofpharmaceutical proteins and small molecules Protein aggregate characterization Stability testing of pharmaceutical proteins under accelerated conditions Computational - proteins Rational protein design based on molecular structure Molecular dynamics simulations of protein – small molecule interactions - Seite proteins under accelerated conditions Biophysical and biochemical protein characterization 06.10.2010 RCPE Präsentationstitel 7 Computational – small molecules Virtual screening In-silico lead optimisation Solubility calculation of small molecules Prediction of crystal structure / polymorphs and morphologies / habits Design and implementation of work flows and data streams through scripting General Literature studies Design and implementation of efficient virtual work flows and data streams through scripting (Knime, Phyton, Perl)